Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

Novartis has another phase 3 trial win in ... The new data – in rare kidney disease IgA nephropathy (IgAN) – comes from the APPLAUSE-IgAN study, with iptacopan achieving a "clinically ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.

The FDA approved Novartis' Vanrafia® (atrasentan), a selective endothelin A receptor antagonist, for reducing proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease ...

Patients requiring treatment for proteinuria reduction in primary immunoglobulin A (IgA) nephropathy now have a solution, with the FDA's accelerated approval of atrasentan (Vanrafia; Novartis)..

“Today’s approval marks an important milestone for people living with IgA nephropathy ... According to Novartis, eGFR data are expected to be announced in 2026. Vanrafia is supplied as ...

"My son was diagnosed with IgA nephropathy long before there were ... care for this disease," said Victor Bultó, President, US, Novartis. "Building on our longstanding legacy in nephrology ...

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.